Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13.
Published June 1, 2022 · Recall initiated: May 13, 2022
Summary
FDA records drug Class III recall D-0896-2022, published June 1, 2022 and initiated May 13, 2022. Recalling firm: GlaxoSmithKline LLC; Status: Terminated; Reported quantity: 328 bottles; Lot: Lot: 2A9E, Exp 1/2027. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.
What to do
Voluntary: Firm initiated · Letter
Get an email if TIVICAY has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- TIVICAY
- Manufacturer
- GlaxoSmithKline LLC
- Distributor
- Nationwide in the U.S.
- UPC
- 0349702227132
- Lot
- Lot: 2A9E, Exp 1/2027
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDATivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton contains one bottleJune 12, 2024
- FDALosartan Pot/HCTZ 100/25 mg 90 Tabs NDC 72189-289-90 Packaged and Distributed By: Direct Rx Dawsonville, GAJune 1, 2022
- FDAQM-4 Papaverine 30 mg/mL Phentolamine 3 mg/mL Alprostadil 300 mcg/mL Atropine 0.2 mg/mL, Multi-Dose 10 mLJune 1, 2022
- FDALosartan Pot/HCTZ 50/12.5 mg 90 Tabs NDC 72189-297-90 Packaged and Distributed By: Direct Rx Dawsonville, GAJune 1, 2022
- FDARE-1 Papaverine 30 mg/mL Phentolamine 3 mg/mL Alprostadil 200 mcg/mL, packaged as a) 2.5 mL Multi Dose vial,June 1, 2022
- FDATivicay (dolutegravir) Tablets 50 mg, 30 Tablet Bottles, Rx Only. Manufactured for: ViiV Health, TRP, NCApril 9, 2014
Questions about this recall
Was Tivicay (dolutegravir) Tablets 50 mg, 30-count Bottle, Rx Only, Manufactured for: ViiV Healthcare RTP, NC 27709, NDC 49702-228-13. recalled?
Yes. FDA published recall D-0896-2022 on June 1, 2022. Reported hazard: Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: TIVICAY. UPC: 0349702227132.